| Drug interactions with grapefruit juice: extent, probable mechanism and clinical relevance U Fuhr Drug safety 18 (4), 251-272, 1998 | 377 | 1998 |
| Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH J Kirchheiner, S Glatt, U Fuhr, U Klotz, I Meineke, T Seufferlein, ... European journal of clinical pharmacology 65, 19-31, 2009 | 353 | 2009 |
| Assessment of CYP1A2 activity in clinical practice: why, how, and when? MS Faber, A Jetter, U Fuhr Basic & clinical pharmacology & toxicology 97 (3), 125-134, 2005 | 344 | 2005 |
| The fate of naringin in humans: A key to grapefruit juice‐drug interactions? U Fuhr, AL Kummert Clinical Pharmacology & Therapeutics 58 (4), 365-373, 1995 | 330 | 1995 |
| Time response of cytochrome P450 1A2 activity on cessation of heavy smoking MS Faber, U Fuhr Clinical Pharmacology & Therapeutics 76 (2), 178-184, 2004 | 317 | 2004 |
| Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. U Fuhr, K Klittich, AH Staib British journal of clinical pharmacology 35 (4), 431-436, 1993 | 315 | 1993 |
| Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach U Fuhr, A Jetter, J Kirchheiner Clinical Pharmacology & Therapeutics 81 (2), 270-283, 2007 | 275 | 2007 |
| Should We Use N-Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses? M Kinzig-Schippers, D Tomalik-Scharte, A Jetter, B Scheidel, V Jakob, ... Antimicrobial agents and chemotherapy 49 (5), 1733-1738, 2005 | 251 | 2005 |
| Pharmacogenetics-based therapeutic recommendations—ready for clinical practice? J Kirchheiner, U Fuhr, J Brockmöller Nature Reviews Drug Discovery 4 (8), 639-647, 2005 | 243 | 2005 |
| Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test I Tantcheva-Poór, M Zaigler, S Rietbrock, U Fuhr Pharmacogenetics and Genomics 9 (2), 131-144, 1999 | 236 | 1999 |
| Toxicokinetics of acrylamide in humans after ingestion of a defined dose in a test meal to improve risk assessment for acrylamide carcinogenicity U Fuhr, MI Boettcher, M Kinzig-Schippers, A Weyer, A Jetter, A Lazar, ... Cancer Epidemiology Biomarkers & Prevention 15 (2), 266-271, 2006 | 235 | 2006 |
| Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva U Fuhr, KL Rost Pharmacogenetics and Genomics 4 (3), 109-116, 1994 | 234 | 1994 |
| Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles P Di Gion, F Kanefendt, A Lindauer, M Scheffler, O Doroshyenko, U Fuhr, ... Clinical pharmacokinetics 50, 551-603, 2011 | 225 | 2011 |
| Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans U Fuhr Clinical pharmacokinetics 38, 493-504, 2000 | 222 | 2000 |
| Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping D Frank, U Jaehde, U Fuhr European journal of clinical pharmacology 63, 321-333, 2007 | 198 | 2007 |
| Inhibitory effects of silibinin on cytochrome P‐450 enzymes in human liver microsomes S Beckmann‐Knopp, S Rietbrock, R Weyhenmeyer, RH Böcker, ... Pharmacology & toxicology 86 (6), 250-256, 2000 | 190 | 2000 |
| Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro U Fuhr, EM Anders, G Mahr, F Sörgel, AH Staib Antimicrobial agents and chemotherapy 36 (5), 942-948, 1992 | 189 | 1992 |
| Pharmacogenetics of oral anticoagulants: a basis for dose individualization S Stehle, J Kirchheiner, A Lazar, U Fuhr Clinical pharmacokinetics 47, 565-594, 2008 | 188 | 2008 |
| The clinical role of genetic polymorphisms in drug-metabolizing enzymes D Tomalik-Scharte, A Lazar, U Fuhr, J Kirchheiner The pharmacogenomics journal 8 (1), 4-15, 2008 | 188 | 2008 |
| An amperometric biosensor with human CYP3A4 as a novel drug screening tool S Joseph, JF Rusling, YM Lvov, T Friedberg, U Fuhr Biochemical pharmacology 65 (11), 1817-1826, 2003 | 184 | 2003 |
Max TaubertDepartment I of Pharmacology, Center for Pharmacology, University Hospital CologneBestätigte E-Mail-Adresse bei uk-koeln.de
